Relamorelin

Drug Profile

Relamorelin

Alternative Names: BIM-28131; BIM-28163; RM 131

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Ipsen
  • Developer Ipsen; Motus Therapeutics
  • Class Gastrokinetics; Growth hormone-releasing hormones; Peptides; Piperidines; Thiophenes
  • Mechanism of Action Ghrelin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Constipation; Diabetic gastroparesis; Gastrointestinal disorders
  • Discontinued Cachexia

Most Recent Events

  • 02 Nov 2016 Efficacy data from a phase IIb trial in Diabetic gastroparesis released by Allergan
  • 27 Oct 2016 Allergan has exercised its option to acquire Motus, and plans to complete the acquisition by the end of 2016
  • 27 Oct 2016 Safety and efficacy data from a phase IIb trial in Diabetic gastroparesis released by Motus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top